MoHAP approves the emergency use of a new COVID-19 vaccine

The Ministry of Health and Prevention (MoHAP) has approved the emergency use of the Sinopharm CNBG’s new recombinant protein vaccine, following the strict monitoring and evaluation of the data of the study conducted in the UAE.

The ministry affirmed that the emergency use of the new vaccine is in full compliance with the regulations and laws for a faster review of licensing procedures.

This is part of the ministry’s painstaking efforts, in cooperation with health authorities, to enhance the prevention of community members from the Covid-19 pandemic.

The study included individuals who were previously vaccinated with two doses of the Sinopharm CNBG’s inactivated vaccine. The seroconversion rate was up to 100% of neutralizing antibodies, along with high safety rates and no side effects recorded among all the participants.

The ministry noted that the positive outcomes achieved of the Covid-19 vaccination campaign, and the commitment of community members to get vaccinated have been an important turning point in the fight against the virus, entering the recovery phase and returning to normal life.

The ministry emphasized the importance for community members to remain committed to preventive and healthy behaviors to preserve the gains and immunize the community from any evolved mutations.